# A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

> **NCT03817463** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 327624 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor
- **DRUG:** Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor

## Key facts

- **NCT ID:** NCT03817463
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-15
- **Primary completion:** 2021-12-10
- **Final completion:** 2021-12-10
- **Target enrollment:** 327624 (ACTUAL)
- **Last updated:** 2024-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03817463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03817463, "A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03817463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*